dc.contributor.author |
Stenzl, Arnulf |
|
dc.contributor.author |
Bedke, Jens |
|
dc.contributor.author |
Maas, Moritz |
|
dc.contributor.author |
Stühler, Viktoria |
|
dc.contributor.author |
Walz, Simon D. |
|
dc.date.accessioned |
2021-07-13T06:37:06Z |
|
dc.date.available |
2021-07-13T06:37:06Z |
|
dc.date.issued |
2021 |
|
dc.identifier.issn |
1744-7682 |
|
dc.identifier.uri |
http://hdl.handle.net/10900/117075 |
|
dc.language.iso |
en |
de_DE |
dc.publisher |
Taylor & Francis Ltd |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1080/14712598.2021.1865910 |
de_DE |
dc.subject.ddc |
570 |
de_DE |
dc.subject.ddc |
610 |
de_DE |
dc.title |
Enfortumab vedotin - next game-changer in urothelial cancer |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20210304112512_00031 |
|
utue.publikation.seiten |
801-809 |
de_DE |
utue.personen.roh |
Maas, Moritz |
|
utue.personen.roh |
Stuehler, Viktoria |
|
utue.personen.roh |
Walz, Simon |
|
utue.personen.roh |
Stenzl, Arnulf |
|
utue.personen.roh |
Bedke, Jens |
|
dcterms.isPartOf.ZSTitelID |
Expert Opinion on Biological Therapy |
de_DE |
dcterms.isPartOf.ZS-Issue |
7 |
de_DE |
dcterms.isPartOf.ZS-Volume |
21 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |